Head & neck · 2025
Neoadjuvant Chemotherapy Followed by Surgery-A Promising Strategy to Reduce Morbidity in Locally Advanced Tongue Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deshpande G A, Rai S, Singh A, Gautam V, Goyal S, Saha R, Tandon S, Gairola M, Upadhya S, Agarwal M
Аннотация
BACKGROUND: Though neoadjuvant chemotherapy (NACT) has not improved survival in oral cancers, its role in tongue cancer remains uncertain.
METHODS: This was a retrospective study of patients with locally advanced oral tongue cancer (Stage III-IVB) to assess response rates, mandibular preservation, and surgical extent post-NACT, along with recurrence and survival outcomes.
RESULTS: Of 72 patients, 20 (27.8%) received NACT, while 52 (72.2%) underwent upfront surgery. In the NACT group, 15 (75%) received TPF chemotherapy for a median of 3 cycles. One patient (5%) had a complete response, and 13 (65%) had a partial response. The clinical benefit rate was 85%. Tumor downstaging occurred in 14 (70%) patients, with 6 (42.9%) requiring less extensive surgery. The mandibular preservation rate was 75%. The pathological complete response was 10%. Local and distant control rates, disease-free survival, and overall survival were comparable.
CONCLUSION: Despite its retrospective design and small sample size, this study suggests that NACT can downstage tumors, improve response rates, and enable less extensive surgery in locally advanced tongue cancer.
METHODS: This was a retrospective study of patients with locally advanced oral tongue cancer (Stage III-IVB) to assess response rates, mandibular preservation, and surgical extent post-NACT, along with recurrence and survival outcomes.
RESULTS: Of 72 patients, 20 (27.8%) received NACT, while 52 (72.2%) underwent upfront surgery. In the NACT group, 15 (75%) received TPF chemotherapy for a median of 3 cycles. One patient (5%) had a complete response, and 13 (65%) had a partial response. The clinical benefit rate was 85%. Tumor downstaging occurred in 14 (70%) patients, with 6 (42.9%) requiring less extensive surgery. The mandibular preservation rate was 75%. The pathological complete response was 10%. Local and distant control rates, disease-free survival, and overall survival were comparable.
CONCLUSION: Despite its retrospective design and small sample size, this study suggests that NACT can downstage tumors, improve response rates, and enable less extensive surgery in locally advanced tongue cancer.